Corcept Therapeutics Incorporated announced preliminary results from the prevalence phase of its ongoing CATALYST study of Cushing?s syndrome (hypercortisolism) in patients with difficult-to-control type 2 diabetes. With a planned enrollment of 1,000 patients, CATALYST is the larger study ever conducted to establish the prevalence of hypercortisolism in this patient population. Of the first 700 patients enrolled in CATALYST, 24% were identified as having hypercortisolism ?

a prevalence rate that has been consistent throughout the study. Final results from the prevalence phase will be presented at the American Diabetes Association?s 84th Scientific Sessions in June. CATALYST is a prospective, Phase 4 study with two parts.

The prevalence phase assesses the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes, which the study defines as hemoglobin A1c greater than 7.5% despite receiving optimal therapies. Patients from this group with a dexamethasone suppression test value greater than 1.8 µg/dL and dexamethasone levels greater than 140 ng/dL are identified as having hypercortisolism. Subject to satisfying additional screening criteria, these patients are eligible to enter CATALYST?s treatment phase, in which they are randomized, 2:1, to receive treatment with either Korlym® or placebo.

CATALYST is being conducted at 35 sites in the United States.